Please assess the completion status of the following clinical trial:

Trial Title: Effect of Taurolidin on Prevention of Bloodstream Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age superior to 18 years~* Home parenteral nutrition on tunnelized central venous catheters~* Bloodstream infection confirmed by differential hemocultures~* Informed consent form signed~* Negative B-HCG test~Exclusion Criteria:~* Subject unable to give his informed consent~* Pregnancy~* Subject who have a two or three-way catheter, or a non-tunnelized central venous catheter~* Hospital related infection~* Central venous catheters placed since less than 15 days~* Neutropenia \< 500 PNN/mm3~* Fungal Infection, polymicrobial who need ablation of the central venous catheters~* No-response to clinical treatment of the Infection~* Septic thrombophlebitis~* Chemotherapy ongoing~* On going malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Use of taurolidine in prevention of bloodstream infection related to central venous access
- B (Type: PLACEBO_COMPARATOR): Use of Physiologic Serum to compare to arm A

Based on this trial design, predict the completion outcome and termination type (if applicable).